Identification & Validation of GPCR1 as a Novel Pancancer ADC Target
- GPCR1 is enriched in multiple types of cancers including solid and heme indications
- SKM104 is a specific anti-GPCR1 antibody with optimal properties for ADC modality
- SKM104-MA-L2 is an anti-GPCR1, exatecan-based ADC showing robust anti-tumour activity in multiple cancer models